Nutritional Science Research on Subclinical Cognitive and Fatigue States
The Problem
Subclinical cognitive and fatigue states affect millions — yet rigorous clinical validation is rare in the nutraceutical category.
Mild Cognitive Impairment
Mild cognitive impairment affects nearly 1 in 5 adults age 65 and older — the largest unaddressed prodromal stage before clinical diagnosis.
Chronic Fatigue Syndrome
Chronic fatigue prevalence has doubled post-pandemic. Up to 10% of infections induce lasting neurobiological dysfunction.
Burnout
Sick days concerning neurobiologically associated burnout rose by 84% in the past decade. At the same time, stress in the workplace keeps increasing.
Validated Products
Double-blind clinical validation is not yet established practice in this product category.
Federal institutions are calling for stricter scientific verification of nutraceutical products.
A Life Science Approach
This is our envisaged approach to the problem outlined above: a transdisciplinary research framework that examines subclinical states at the level of their biochemical pathways rather than their symptoms.
Neuroscience
Top-down perspective on neurotransmitter synthesis, inflammatory signalling, and mitochondrial energy supply in the central nervous system.
Nutrition Science
Bottom-up perspective on bioavailable precursors and cofactors and their role in nutrient supply relevant to cognitive performance.
Clinical Validation
Planned double-blind longitudinal trials in subclinical cohorts — cognitive change, fatigue, chronic stress — with multi-modal neurobiological endpoints.
Three Formulations. One Day.
Circadian-aligned formulations — each addresses the biological pathways characteristic of its time window.
The three formulations are circadian-aligned: complementary pathways across morning, midday, and evening reduce overlap while converging on shared research endpoints — one integrated system, not three isolated products.
Morning
Research Focus: Mitochondrial and Catecholaminergic Pathways
Research Targets Under Investigation
Not statements of product effect.
- 1Mitochondrial function and ATP synthesis pathways
- 2Catecholaminergic precursor availability
- 3AMPA-receptor signalling
Midday
Research Focus: Cholinergic Pathways and Neuroplasticity
Research Targets Under Investigation
Not statements of product effect.
- 1Cholinergic precursor availability
- 2Phospholipid metabolism and neurotrophic signalling
- 3Cerebral perfusion and thyroid-related metabolism
Evening
Research Focus: GABAergic Pathways and Nocturnal Regeneration
Research Targets Under Investigation
Not statements of product effect.
- 1GABAergic signalling and serotonin precursor availability
- 2Circadian rhythm and sleep architecture
- 3Antioxidant synthesis and neurotrophic signalling
Six Ingredient Classes
All formulations are built exclusively from these well-characterised nutrient classes.
Minerals & Trace Elements
Essential cofactors for CNS enzymatic processes, neurotransmitter synthesis, and mitochondrial electron transport chain function.
Vitamins
Critical for one-carbon methylation cycles, myelin sheath integrity, antioxidant defense, and neurohormone synthesis.
Amino Acids
Direct biosynthetic precursors to catecholaminergic, serotonergic, cholinergic, and GABAergic pathways — the substrate layer of neurotransmission.
Lipids
Structural components of neuronal membranes, synaptic vesicle formation, and myelination — essential for signal transduction fidelity.
Vitaminoids & Compounds
Mitochondrial electron chain cofactors, redox regulators, and antioxidant network components targeting oxidative stress.
Plant & Mushroom Extracts
Adaptogenic phytocompounds whose reported mechanisms include NGF/BDNF signalling and HPA-axis modulation.
Core Values
- Impactfulness first (bioavailable ingredients, synergistic mechanisms & committed to empirical validation);
- One team, one world (professional as well as interpersonal coherence & corporate social responsibility);
- Reign of velocity (rapid movement and evolution by carefully building a strong foundation);
And everything is covered under the umbrella of science, because we are technocrats.
Rigorous Research Design
Double-blind, longitudinal crossover trials in subclinical populations — with multi-modal neurobiological endpoints across four phased prevention levels (primary through tertiary).
Psychometrics
Standardized subclinical screening: MCI severity, fatigue indices, burnout staging, neuropsychological rating scales
Blood & Urine
Neurotransmitter precursors, catecholamines, acetylcholine, GABA, inflammatory markers, mitochondrial function proxies
EEG
Resting-state and task-evoked cortical activity — theta/alpha power as biomarkers for subclinical cognitive impairment
fMRI
Functional connectivity in prefrontal cortex, hippocampus, and default mode network — structural correlates of subclinical decline
Study Phases
Subclinical-first design — escalating from primary prevention to borderline clinical populations
Pilot Study
Healthy adults with subclinical risk markers, 50% dosage, primary prevention design
Subclinical Population
Screened subclinical cohort, secondary prevention design, 75% dosage
Clinical Extension
Diagnosed borderline cohort, exploratory secondary endpoints, 100% dosage
Replication
Tertiary prevention post-convalescence; independent verification in subclinical cohort, 50% dosage
Transdisciplinary Team
Psychology, medicine, pharmacy, and business — united by the mission to improve human cognition.
Max Vogel
Founder & CEO
Clinical Psychology (M.Sc.) & Organizational Development
Product formulation, research design, psychometric support, strategic leadership
LinkedInMarc Peters
Chief Financial Officer
Business IT (B.Sc.) & Business Law (LL.B.)
Accounting and controlling, tax regulations, investment procedures, legal affairs
LinkedInDr. Maxim Kots
Chief Scientific & Medical Officer
Clinical Development & Medical Affairs (M.D.)
Scientific processing, study execution, neurobiological diagnostics, safety regulations
LinkedInAnton Schiller
Chief Operating & Developing Officer
Pharmacy (State License) & Quality Assurance
Pharmaceutical realization, contract manufacturing, supply chain, digitalization
LinkedInScientific Advisors
Dr. Stefan Schulreich
Neuroscience
Dr. Shahrouz Jafarzadeh
Statistics
Nicole Langer
Psychometrics
Dr. Anton Kolosov
Clinical Medicine
Mentors & Collaborators
Prof. Dr. Meike Watzlawik
Psychology & Organizational Development
Christian Walker
Microbiology & Neuro-Startups
Dr. Eva-Maria Hempe
Health & Sales Strategy
Deutsches Institut für Ernährungsforschung (DIfE)
Study implementation, recruitment, bioavailability
Pensatech Pharma
Drug delivery questions
Market Opportunity
The nutraceutical neurological market is driven by ageing populations, post-viral syndromes, and rising demand for scientifically substantiated preventive products. The headline figures below are all stated as of 2022 reporting.
Global market size (2022)
CAGR, 2022 baseline
Top German competitor revenue (2022)
Strategic outlook
Digital health
Potential synergies with digital phenotyping and adherence tools are under exploration — no commitments to specific products yet.
Pharmaceuticals
Future combinations or sequencing with pharmacotherapy may be evaluated where evidence and regulation align — exploratory only at this stage.
Microbiome
Product concepts linking gut–brain axes and targeted microbiome support remain prospective R&D directions, not current claims.
Early Cognitive Change
Adults with early cognitive markers not yet meeting diagnostic thresholds — a large population segment with no established nutritional standard of care
Fatigue States
Long-COVID, CFS and burnout-related fatigue cohorts with measurable mitochondrial and immunological findings but limited therapeutic options
Prevention-Oriented Aging Adults
Individuals interested in preventive nutrition approaches and in monitoring their own biomarkers
Why Neurotrition Wins
Scientific Legitimacy
Every ingredient is backed by peer-reviewed mechanistic evidence. No proprietary blends — full transparency on dosages and rationale.
Synergistic Formulation
Ingredients are co-selected for pharmacokinetic compatibility and biochemical synergy — not stacked additively but designed as a system.
Clinical Validation
Double-blind crossover trials in subclinical populations are planned — the endpoint design goes beyond self-reporting to include EEG and fMRI biomarkers.
Patent Strategy in Preparation
Proprietary circadian-aligned delivery system and formulation ratios, with IP protection being pursued — intended to create durable defensibility against fast-followers.